Dexamethasone is classified as a corticosteroid and is commonly used among cancer patients to decrease the amount of swelling around the tumor. Among patients with cancer, in particular brain tumors, seizures can become a daily routine in their everyday lives. To counteract the seizures, an antiepileptic drug such as phenytoin is administered to act as an anticonvulsant. Phenytoin and dexamethasone are frequently administrated concurrently to brain cancer patients. A previous study has shown that phenytoin serum concentration decreases when administrated concurrently with dexamethasone. Thus, it is important to monitor the concentration of these two drugs in biological samples to ensure that the proper dosages are administrated to the patients. This study aims to develop an effective extraction and detection method for dexamethasone and phenytoin. A reverse-phase high-performance liquid chromatography (HPLC) method with UV/Vis detection has been developed to separate phenytoin and dexamethasone at 219 nm and 241 nm respectively from urine samples. The mobile phase consists of a mixture of 0.01 M KH2PO4, acetonitrile, and methanol adjusted to pH 5.6 (48:32:20) and is pumped at a flow rate of 1.0 mL/min. Calibration curves were prepared for phenytoin and dexamethasone (r2 > 0.99). An efficient solid-phase extraction (SPE) method for the extraction of dexamethasone and phenytoin from urine samples was developed with the use of C-18 cartridges. The percent recovery for phenytoin and dexamethasone is 95.4% (RSD = 1.15%) and 81.1% (RSD = 3.56%) respectively.
References
[1]
Entringer, S. (2023) Dexamethasone. https://www.drugs.com/dexamethasone.html
[2]
Mulvenna, P., Barton, R., Wilson, P., Faivre-Finn, C., Pugh, C., Langley, R., et al. (2010) Quality of Life in Patients Receiving Optimal Supportive Care (Including Dexamethasone) Plus Whole-Brain Radiotherapy in the Treatment of Inoperable Brain Metastases from Non-Small Cell Lung Cancer: The MRC QUARTZ Randomised Trial. Lung Cancer, 67, S31. https://doi.org/10.1016/s0169-5002(10)70095-7
[3]
Oberndorfer, S., Schmal, T., Lahrmann, H., Urbanits, S., Lindner, K. and Grisold, W. (2002) The Frequency of Seizures in Patients with Primary Brain Tumors or Cerebral Metastases. An Evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wiener KlinischeWochenschrift, 114, 911-916. https://pubmed.ncbi.nlm.nih.gov/12528323/
[4]
Dexamethasone for Brain Tumors: Information for Patients. https://www.ouh.nhs.uk/patient-guide/leaflets/files/5613Pdexamethasone.pdf
[5]
Wu, A., Weingart, J.D., Gallia, G.L., Lim, M., Brem, H., Bettegowda, C., et al. (2017) Risk Factors for Preoperative Seizures and Loss of Seizure Control in Patients Undergoing Surgery for Metastatic Brain Tumors. World Neurosurgery, 104, 120-128. https://doi.org/10.1016/j.wneu.2017.05.028
[6]
Guzzo, E.F.M., de Lima Rosa, G., Domingues, A.M., Padilha, R.B. and Coitinho, A.S. (2023) Reduction of Seizures and Inflammatory Markers by Betamethasone in a Kindling Seizure Model. Steroids, 193, Article 109202. https://doi.org/10.1016/j.steroids.2023.109202
[7]
Inselman, A.L. and Hansen, D.K. (2014) Phenytoin. In: Wexler, P., Ed., Encyclopedia of Toxicology, 3rd Edition, Elsevier, 895-897. https://www.sciencedirect.com/topics/medicine-and-dentistry/phenytoin https://doi.org/10.1016/b978-0-12-386454-3.00771-5
[8]
Dang, L.T., Quinonez, S.C., Becka, B.R., Isom, L.L. and Joshi, S.M. (2020) Dramatic Improvement in Seizures with Phenytoin Treatment in an Individual with Refractory Epilepsy and a SCN1B Variant. Pediatric Neurology, 108, 121-122. https://doi.org/10.1016/j.pediatrneurol.2020.03.012
[9]
von Winckelmann, S.L., Spriet, I. and Willems, L. (2008) Therapeutic Drug Monitoring of Phenytoin in Critically Ill Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28, 1391-1400. https://doi.org/10.1592/phco.28.11.1391
[10]
Elsayed, R.M., Mohamed, A.S., Tawfik, M.K. and Hagras, M.M. (2023) Effect of Cyclooxygenase Inhibition on P-Glycoprotein Expression and Phenytoin Level in Brain Tissue of Pilocarpine Induced Epilepsy in Rats. Journal of Biosciences and Medicines, 11, 169-191. https://doi.org/10.4236/jbm.2023.118014
[11]
Mclelland, J. and Jack, W. (1978) Phenytoin/Dexamethasone Interaction: A Clinical Problem. The Lancet, 311, 1096-1097. https://doi.org/10.1016/s0140-6736(78)90938-8
[12]
Jubiz, W., Meikle, A.W., Levinson, R.A., Mizutani, S., West, C.D. and Tyler, F.H. (1970) Effect of Diphenylhydantoin on the Metabolism of Dexamethasone. New England Journal of Medicine, 283, 11-14. https://doi.org/10.1056/nejm197007022830103
[13]
Wong, D.D. (1985) Phenytoin-Dexamethasone: A Possible Drug-Drug Interaction. JAMA, 254, 2062-2063. https://doi.org/10.1001/jama.1985.03360150038012
[14]
Lackner, T.E. (1991) Interaction of Dexamethasone with Phenytoin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 11, 344-347. https://doi.org/10.1002/j.1875-9114.1991.tb04300.x
[15]
Ghosh, C., Lazarus, H., Hewlett, J. and Creger, R. (1992) Fluctuation of Serum Phenytoin Concentrations during Autologous Bone Marrow Transplant for Primary Central Nervous System Tumors. Journal of Neuro-Oncology, 12, 25-32. https://doi.org/10.1007/bf00172454
[16]
Recuenco, I., Espinosa, E., García, B. and Carcas, A. (1995) Effect of Dexamethasone on the Decrease of Serum Phenytoin Concentrations. Annals of Pharmacotherapy, 29, 935-935. https://doi.org/10.1177/106002809502900918
Skrabalak, D.S. and Maylin, G.A. (1982) The Extraction and Isolation of Dexamethasone-Related Compounds. Journal of Pharmacological Methods, 8, 291-297. https://doi.org/10.1016/0160-5402(82)90046-8
[19]
Yaripour, S., Nojavan, S., Khoshayand, M.R. and Mohammadi, A. (2020) Electromembrane Extraction of Phenytoin from Biological Fluids: A Survey on the Effects of Molecularly Imprinted Polymer and Carbon Nanotubes on Extraction Efficiency. Microchemical Journal, 156, Article 104800. https://doi.org/10.1016/j.microc.2020.104800
